VTRS at a glance
Viatris (VTRS, SEC CIK 1792044) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 17, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Viatris (VTRS) reported revenue of $14.3 billion (down 3.0% from FY2024) and a net loss of $3.5 billion. Diluted EPS was -$3.00.
- As of September 30, 2026, 49 institutional investment managers tracked by SignalX reported holding Viatris (VTRS) shares worth $8.3 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $14.3B
- −3.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 49 funds
- $8.3B · −1 vs prior quarter
- Latest 8-K
- Nov 17, 2026
- Item 7.01 · Item 2.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Global pharma company delivering generics, branded generics, and innovative medicines to ~1B patients across 165+ countries with 30,000+ employees and 27 manufacturing sites
- Five positive Phase 3 readouts in 2025: meloxicam acute pain, low-dose estrogen patch (FDA action target July 30, 2026), LYNX-2 night driving (MR-142), VEGA-3 presbyopia (MR-141, FDA action H2 2026), and EFFEXOR Japan GAD
- EWSR launched 2025: up to ~10% global workforce reduction, $700M–$850M in restructuring charges, targeting $600M–$700M in savings once fully implemented
- 2025 total revenues $14.30B; returned >$1B to shareholders (~$500M buybacks + $561M dividends) despite divestiture headwinds and Indore FDA warning letter impact
- Acquired Aculys Pharma (Oct 2025) for Japan-exclusive rights to pitolisant (narcolepsy/sleep apnea) and Spydia® Nasal Spray: sharpest pivot yet toward patent-protected innovative assets in Japan
Risk Factors
- FDA warning letter & import alert on Indore, India oral dose facility restricting U.S. distribution, with unrecovered revenue impact in FY2025
- U.S. tariffs on pharmaceutical imports (including API) threatening cost structure; competitors may be disproportionately less affected
- Top 3 customers ~25% of net sales; limited manufacturing sites plus post-divestiture API supply dependence on single external vendor
- Inflation Reduction Act (2022) drug price negotiation and most-favored-nation pilot programs risk compressing innovative pipeline product margins
- Significant indebtedness with refinancing risk at higher rates; $2.94B goodwill impairment charge taken in 2025
Management Discussion & Analysis
- Revenue $14.30B, down 3% YoY ($439M decline); Indore facility impact ~$370M drag; Greater China only growth segment, +8% to $2.33B
- Gross margin 35% vs 38%; adjusted gross margin 56% vs 58%; operating loss $(2.66B) vs near-breakeven $10M in 2024, driven by $2.94B goodwill impairment
- Best segment: Greater China +8% constant currency; worst: JANZ -11% ($152M decline) from government price cuts and Indore impact
- Operating cash flow $2.32B (up $13M YoY); capex $378.8M; buybacks $500.5M; dividends $561.2M; 2026 capex guided $350M–$450M
- 2026 restructuring program targets $600M–$700M savings, $700M–$850M pre-tax charges; Nashik plant fire (Feb 2026) adds supply risk; biosimilar non-compete expiry unlocks new revenue opportunity
AI summary of the VTRS 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New acquisition risk: Pacira transaction may fail or face delays due to tender, regulatory, legal and closing conditions
- Most material update: Pacira integration may underperform, limiting anticipated benefits, synergies and operating efficiencies
- Regulatory risk: Hart-Scott-Rodino waiting-period expiration required before Pacira offer completion
- Operational risk: Viatris may fail to retain Pacira talent supporting commercial, market access, medical affairs and R&D capabilities
- Financial risk: Transaction setbacks could affect cash flows, dividends, share repurchases and stock price
Management Discussion & Analysis
- Q3 revenue $3.75B vs $3.76B, down $10.4M YoY, essentially flat
- Gross margin 38% vs 36%; adjusted gross margin approximately 58% vs 56%
- Best segment Greater China: $702.6M, up 14%; worst Emerging Markets: $529.1M, down 7%
- Operating cash flow $1.67B through September, up $169.4M; repurchases $150.0M in Q3
- Nashik disruption: approximately $100M Q4 revenue impact; production expected to resume Q1 2027
AI summary of the VTRS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Viatris announced consummation of the Merger, marking completion of a material corporate transaction
- Investors should review Exhibit 99.1 for merger consideration, strategic rationale and expected financial impact
Item 2.01: Completion of Acquisition or Disposition of Assets
- Viatris completed Pacira acquisition on November 17, 2026, making Pacira a wholly owned subsidiary
- Offer price $36.50 per share in cash, with 32,929,780 shares tendered, representing 66.46% ownership
Item EX-99.1: Item EX-99.1
- Viatris completed Pacira acquisition, adding Pacira’s non-opioid pain portfolio to its U.S. innovative medicines business
- Cash consideration of $36.50 per share, with approximately 32,929,780 shares tendered, representing 66.46% of outstanding shares
Item 2.02: Results of Operations and Financial Condition
- Viatris reported financial results for the period ended September 30, 2026
- Press release issued November 5, 2026, with detailed results in Exhibit 99.1
Item 8.01: Other Events
- Conference call and live webcast at 8:30 a.m. ET to review Viatris financial results
- Results cover the period ended September 30, 2026
Item EX-99.1: Item EX-99.1
- Q3 revenue $3.75B was flat, while adjusted EBITDA rose 4% to $1.20B and adjusted EPS increased 6% to $0.71
- U.S. GAAP net loss widened to $325M, driven primarily by higher income taxes on losses with limited realizable tax benefits
Item 8.01: Other Events
- Viatris and Pacira announced a merger agreement on October 8, 2026, initiating a proposed acquisition subject to closing conditions
- Tender offer has not commenced, with Viatris expected to file Schedule TO and Pacira Schedule 14D-9
Item 1.01: Entry into a Material Definitive Agreement
- Viatris agreed to acquire Pacira for $36.50 per share in cash through a tender offer
- Offer requires more than 50% of Pacira shares tendered, with no financing condition
Item EX-99.2: Item EX-99.2
- Viatris plans to acquire Pacira BioSciences, signaling expansion into specialty pharmaceuticals
Item EX-99.1: Item EX-99.1
- Viatris agreed to acquire Pacira for $36.50 per share in cash, valuing equity at $1.65 billion
- Pacira generated $746 million revenue and $177 million adjusted EBITDA for the twelve months ended June 30, 2026
AI summaries of VTRS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for VTRS
Don't miss the next VTRS filing
- Alerts as it files. A push when VTRS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut VTRS, by share count.
- Ask anything. An AI agent that reads every VTRS filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Groothuis Leo Frans | A | Sep 30, 2026 | 2,469 | $17.72 |
| SIMMONS DAVID S | A | Sep 30, 2026 | 2,117 | $17.72 |
| Enrietti Andrew | M | Aug 15, 2026 | 999 | - |
| Enrietti Andrew | F | Aug 15, 2026 | 435 | $16.23 |
| Enrietti Andrew | F | Aug 15, 2026 | 10,931 | $16.23 |
| Enrietti Andrew | M | Aug 15, 2026 | 998.364 | - |
| Enrietti Andrew | M | Aug 15, 2026 | 25,134 | - |
| Enrietti Andrew | M | Aug 15, 2026 | 25,134 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $14.7B | $14.3B |
| Gross Profit | - | $5.6B | $5.0B |
| Operating Income | - | $10.1M | -$2.7B |
| Net Income | - | -$634.2M | -$3.5B |
| Gross Margin | - | 38.3% | 35.2% |
| Op. Margin | - | 0.1% | -18.7% |
| Net Margin | - | -4.3% | -24.7% |
| Balance Sheet | |||
| Total Assets | $47.7B | $41.5B | $37.2B |
| Equity | $20.5B | $18.6B | $14.7B |
| ROE | - | -3.4% | -23.9% |
| Per Share | |||
| EPS | - | $-0.53 | $-3.00 |
| Cash Flow | |||
| Operating CF | - | $2.3B | $2.3B |
| CapEx | - | $326.0M | $378.8M |
Source: XBRL data in Viatris (VTRS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate VTRS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 49 | $8.31B |
| Q2 2026 | 50 | $9.48B |
| Q1 2026 | 48 | $7.15B |
| Q4 2025 | 42 | $6.99B |
| Q3 2025 | 43 | $5.68B |
| Q2 2025 | 44 | $4.87B |
| Q1 2025 | 39 | $3.17B |
| Q4 2024 | 37 | $4.14B |
- D.E. Shaw & Co+1.85M (+234%)
- Citigroup+1.78M (+41%)
- Invesco Ltd+1.28M (+6%)
- Citadel Advisors LLC+891.2K (+177%)
- Bridgewater Associates LP+453.6K (+27%)
- Dimensional Fund Advisors−12.77M (-43%)
- T. Rowe Price Group−9.49M (-14%)
- State Street Corp−6.69M (-13%)
- Goldman Sachs Group−4.53M (-33%)
- BNY Mellon−1.71M (-12%)
- Renaissance Technologies LLC+419.2K
- FMR LLC (Fidelity)−96.66M
- Equitable Holdings Inc−50.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 352 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
VTRS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 17, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Oct 8, 2026 | - | Analysis | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| SC 13G | Aug 6, 2026 | - | - | |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 1, 2026 | - | Analysis | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 8-K | Jun 18, 2026 | - | Analysis | - |
| 8-K | Jun 15, 2026 | - | Analysis | - |
| 8-K | May 15, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 8-K | May 4, 2026 | - | Analysis | - |
| SC 13G | Apr 30, 2026 | - | - | |
| 4 | Apr 16, 2026 | - | - | - |
| 4 | Mar 24, 2026 | - | - | - |
| 4 | Mar 10, 2026 | - | - | - |
| 4 | Mar 10, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
VTRS SEC filings: frequently asked questions
Which institutions hold VTRS stock?
As of September 30, 2026, the largest Viatris (VTRS) holders among the 13F filers tracked by SignalX were BlackRock ($1.5 billion), Vanguard Capital Management LLC ($1.3 billion), T. Rowe Price Group ($1.0 billion), Vanguard Portfolio Management LLC ($962.3 million), State Street Corp ($821.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was VTRS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Viatris (VTRS) reported revenue of $14.3 billion (down 3.0% from FY2024) and a net loss of $3.5 billion. Diluted EPS was -$3.00. The figures come from the XBRL data in the 10-K.
What are the main risks in VTRS's latest 10-K?
In the 10-K filed February 26, 2026, Viatris (VTRS) flagged: FDA warning letter & import alert on Indore, India oral dose facility restricting U.S. distribution, with unrecovered revenue impact in FY2025. U.S. tariffs on pharmaceutical imports (including API) threatening cost structure; competitors may be disproportionately less affected. (AI summary of the Risk Factors section.)
What did VTRS report in its latest 8-K?
Viatris (VTRS) filed an 8-K on November 17, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 2.01 (Completion of Acquisition or Disposition of Assets). Viatris announced consummation of the Merger, marking completion of a material corporate transaction.
What are the latest VTRS SEC filings?
Viatris (VTRS) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 17, 2026 and a Form 4 insider filing on October 2, 2026.
What is VTRS's SEC CIK number?
Viatris (VTRS)'s SEC Central Index Key (CIK) is 1792044. EDGAR lists every VTRS filing under that number.
Ask anything about VTRS
The research agent reads VTRS's filings, financials, insider trades and 13F holders, then answers with sources.